Full TitleDurvalumab with Thoracic Radiation Therapy Without Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (DART)
Stage II or III non-small cell lung cancer would normally be treated with sequential chemotherapy followed by radiation therapy. The purpose of this study is to see if durvalumab immunotherapy instead of chemotherapy used during and after a course of radiation therapy can delay the worsening of disease. Durvalumab is given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have stage II or III non-small cell lung cancer that cannot be surgically removed or treated with standard sequential chemotherapy followed by radiation therapy.
- Patients may not have previously received chemotherapy for this diagnosis of lung cancer, nor any prior immunotherapy or radiation therapy to the chest.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Andreas Rimner at 212-639-6025.